The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Sharad A. Ghamande
Consulting or Advisory Role - Seagen
Speakers' Bureau - Eisai; Tesaro/GSK
Research Funding - Abbvie (Inst); Advaxis (Inst); Akeso Biopharma (Inst); Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ellipses Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Merck Serono (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst)
 
Yuka Kasamatsu
No Relationships to Disclose
 
Marta Gil-Martin
Speakers' Bureau - AstraZeneca
 
Elisabeth J. Diver
Consulting or Advisory Role - Curio Science; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - Aravive (Inst); Tesaro/GSK (Inst)
Patents, Royalties, Other Intellectual Property - Textbook royalties CRC Press
Travel, Accommodations, Expenses - Tempus
 
Genevieve Jehl
Employment - Merck KGaA
 
Stephan A. Gleicher
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Surendra Chaudhary
Employment - EMD Serono
Stock and Other Ownership Interests - EMD Serono
Travel, Accommodations, Expenses - EMD Serono
 
Yulia Vugmeyster
Employment - EMD Serono
Stock and Other Ownership Interests - Alexion Pharmaceuticals
Patents, Royalties, Other Intellectual Property - EMD Serono
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Takeda
Consulting or Advisory Role - Kaken Pharmaceutical; MSD K.K
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical